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ACE and ACE2: their role to balance 
the expression of angiotensin II and 
angiotensin-(1–7)
MC Chappel1  and CM Ferrario1
The discovery of angiotensin-converting enzyme 2 (ACE-2) has revealed 
a far more complex enzymatic cascade that may influence the renin-
angiotensin system within the kidney, specifically the expression of the 
functional products angiotensin II (Ang II) and Ang-(1-7). The regulation 
of this critical system involved in blood pressure control must now 
encompass the integral relationship of ACE and ACE-2 activities.
Kidney International (2006) 70, 8–10. doi:10.1038/sj.ki.5000321
In this issue, Tikellis et al.1 document the 
developmental expression of both angio-
tensin-converting enzyme (ACE) and its 
novel homologue, angiotensin-convert-
ing enzyme 2 (ACE2), in the kidneys of 
the normotensive Wistar Kyoto (WKY) 
rat strain and the spontaneously hyper-
tensive rat (SHR). Th ese studies build on 
the original report by Penninger and col-
leagues, who found that reduced expression 
of renal ACE2 in three distinct models of 
hypertension correlated with the hyperten-
sive phenotype.2 In that study, the ACE2-
null mice expressed higher circulating and 
cardiac tissue levels of angiotensin II (Ang 
II). Moreover, our preliminary data dem-
onstrate that ACE2 is the predominant 
pathway for the metabolism of Ang II in 
the murine heart, providing additional 
evidence that ACE2 is a key component of 
the tissue renin–angiotensin system (RAS) 
(PJ Garabelli et al., Hypertension 2003; 
43: 1349, abstr.). ACE, a zinc metalloen-
dopeptidase that functions as a carboxyl-
directed dipeptidase, converts Ang I to Ang 
II and also inactivates bradykinin. ACE2 
is the first known homologue of ACE, 
exhibiting over 60% sequence similarity to 
ACE.3,4 Unlike ACE, ACE2 is resistant to 
ACE inhibitors, and ACE2 catalytic activity 
is exerted by cleavage of a single amino acid 
residue at the carboxyl terminus. Although 
ACE2 was fi rst shown to cleave Ang I to 
Ang 1–9 given its close homology to ACE,3 
subsequent studies revealed that Ang II 
exhibits a far greater catalytic rate than 
Ang I.5 To date, only Li et al.6 have found 
that Ang I may be a preferred substrate for 
ACE2 in proximal tubules from rat kidney, 
as, in their study, they found no evidence 
for ACE2-dependent generation of Ang 
1–7 from Ang II. Th e inability of the proxi-
mal epithelial ACE2 to cleave Ang II to Ang 
1–7 is surprising particularly given the lack 
of evidence for ACE2 isozymes. Moreover, 
we and others fi nd signifi cant ACE2 activ-
ity with the use of high-performance liquid 
chromatography separation to quantify the 
conversion of Ang II to Ang-(1–7) in the 
membrane fraction of the rat renal cor-
tex or renal homogenates.7,8 Th e issue of 
whether ACE2 participates in the tubular 
processing of Ang II and Ang-(1–7) is an 
extremely important one given that the 
proximal tubules contain the highest den-
sity of ACE2 and that these peptides exhibit 
diff erent actions within the kidney.9
In the study by Tikellis and colleagues,1 
the developmental expression of ACE2 
was compared with that of ACE. Th e gen-
esis of hypertension in the SHR is still not 
resolved but most likely involves the RAS, 
and the critical period for the develop-
ment of the hypertension is approximately 
5–7 weeks of age. Indeed, blockade of the 
RAS by ACE inhibition or Ang II type 1 
receptor (AT1 receptor) antagonists is 
known to have a long-lasting effect on 
blood pressure that exceeds the period of 
treatment. Tikellis et al.1 demonstrate that, 
in comparison with the WKY strain, ACE2 
mRNA and enzyme activity was increased 
in 1-day-old SHR neonates, but reduced at 
42 and 80 days. Th e predominant expres-
sion of ACE2 in both strains was found in 
the proximal-tubule elements; however, 
immunocytochemical staining for ACE2 
was also evident in the glomerulus, and 
the extent of staining was increased in the 
SHR. Although a reduction in renal ACE2 
may conceivably contribute to an elevation 
in blood pressure in the SHR, the authors 
also found that renal ACE mRNA and 
activity were signifi cantly reduced in both 
the neonate and the adult SHR. Th us, the 
issue of whether a shift  to lower ACE2 in 
the presence of reduced ACE activity con-
tributes to the hypertensive phenotype 
remains to be investigated. Although it is 
plausible that reduced ACE2 gene expres-
sion will favor increased levels of Ang II 
through reduced conversion into Ang-
(1–7), it is necessary to also consider that 
ACE is the primary enzyme involved in the 
inactivation of Ang-(1–7).10 Measurements 
of renal tissue concentrations of both Ang 
II and Ang-(1–7) will be required to answer 
this question. Moreover, it is important to 
emphasize that ACE and ACE2 probably 
function in concert within tissues to con-
stitute an infl uential point in the actions 
of the RAS pathway, as proposed recently 
by Ferrario et al.11 As is mentioned above, 
a reduction in ACE, although depleting 
Ang II as a substrate for ACE2 to be sub-
sequently converted to Ang-(1–7), will 
increase the overall level of Ang I, which 
is directly converted to Ang-(1–7) by the 
action of tissue-specifi c endopeptidases.12 
Until an age-dependent correlation of 
the change in renal content of Ang II and 
Ang-(1–7) is obtained, it will not be pos-
sible to discern the functional implications 
of the alterations in ACE and ACE2 that 
were observed by Tikellis et al.1 Certainly, 
the signifi cance of the current fi ndings is 
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further complicated by the fact that at least 
a fraction of renal Ang II and possibly Ang-
(1–7) is derived from receptor-mediated 
uptake of blood-derived peptides.13,14  Th e 
extent to which ACE2 participates in the 
catabolism of sequestered Ang II from the 
circulation is also unknown.
Finally, one must acknowledge that the 
reliance on the measurement of enzyme 
activity with synthetic substrates pre-
cludes a direct comparison of ACE and 
ACE2 activities. Although fluorescent 
substrate assays provide a sensitive and 
effi  cient means to quantify activity, pro-
vided adequate controls are used, the 
ACE2 substrate is not entirely specifi c for 
ACE2, as other peptidases may cleave this 
substrate. Indeed, the study by Tikellis et 
al.1 emphasizes the inclusion of the prolyl 
oligopeptidase inhibitor z-pro-prolinal to 
prevent hydrolysis of the Pro–Lys bond of 
the substrate. Th e use of the non-peptide 
ACE2 inhibitor MLN-4760 as utilized in 
the present study ensures specifi city of 
the fl uorescent substrate in contrast to 
the general metalloprotease inhibitors 
such as EDTA or o-phenanthroline. Th e 
DX-600 compound is also a potent ACE2 
inhibitor; however, this peptide is likely 
not to be resistant to proteolysis in tis-
sue homogenates, and the resultant frag-
ments may exhibit additional inhibitory 
activity against other peptidases, which 
may explain the antihypertensive actions 
of this agent in the SHR.15 Although there 
are no technical issues with the assays 
used by Tikellis et al.,1 and both activity 
and mRNA levels closely match, the com-
parative activities of ACE and ACE2 in 
the kidney cannot be ascertained with the 
current approach. At this point, the use 
of the endogenous substrates Ang I and 
Ang II assayed under identical conditions 
will provide an accurate assessment of the 
balance of both activities in the kidney 
and other tissues. In this regard, both 
ACE and ACE2 were increased in the 
lungs of nutritionally deprived rats that 
exhibit higher blood pressure; however, 
ACE activity was 100-fold greater than 
ACE2 activity (rate of Ang-(1–7) pro-
duced),8 and it is diffi  cult to conclude that 
ACE2 would eff ectively buff er the changes 
in pulmonary ACE in this model of 
fetal programming.
Although Tikellis et al.1 take the view-
point that ACE and ACE2 constitute a 
counter-regulatory mechanism within 
the kidney, their results reveal a some-
what similar downregulation of the two 
enzymes in the WKY rat and the SHR 
during development. Th is scenario is of 
interest in light of our own studies that 
first revealed that Ang II, through the 
AT1 receptor, appears to negatively regu-
late ACE2 expression in the heart, kidney, 
and astrocytes.7,16,17 Th e overall regula-
tion of ACE2 may be more complex than 
anticipated given the pronounced diff er-
ences in ACE2 mRNA expression within 
the kidneys of the normotensive Lewis 
(Figure 1, upper panel) and hypertensive 
mRen2.Lewis (Figure 1, lower panel) rats 
following the ACE inhibitor lisinopril or 
the AT1 receptor antagonist losartan. Th e 
inset panel of Figure 1 illustrates that both 
cortical and medullary levels of Ang II are 
elevated in the mRen2.Lewis rat and sug-
gests that blockade of an increased RAS 
results in an enhanced response in the 
expression of ACE2. Indeed, the increase 
in ACE2 is consistent with elevated levels 
of Ang-(1–7) following AT1 receptor or 
ACE blockade, as well as the functional 
contribution of Ang-(1–7) to the blood 
pressure-lowering eff ects of these agents.17 
Elucidation of the regulatory mechanisms 
for ACE2, and the functional aspects of 
the enzyme in distinct tissue compart-
ments, remain two key areas of continu-
ing study.
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Figure 1 | Differential response of renal angiotensin-converting enzyme 2 mRNA expression 
to renin–angiotensin system blockade in normotensive and hypertensive rats. Renal 
angiotensin-converting enzyme 2 (ACE2) mRNA levels were determined in the renal cortex of 
normotensive Lewis (upper panel) and hypertensive mRen2.Lewis (lower panel) rats after a 2-week 
treatment with either the ACE inhibitor lisinopril (20 mg per kg per day) or the angiotensin II type 1 
receptor antagonist losartan (10 mg per kg per day) (CMF et al., unpublished observations). Inset: 
Cortical and medullary tissue levels of angiotensin II (Ang II) in the Lewis and mRen2.Lewis rats. 
*P < 0.05 versus vehicle (n = 8 per group); #P < 0.05 versus Lewis (n = 5 per group).18
10   Kidney International (2006) 70
commentar y
see original articles on pages 139 and 144
Non-invasive assessment of kidney 
oxygenation: a role for BOLD MRI
RP Mason1
Blood oxygen level-dependent (BOLD) contrast magnetic resonance 
imaging (MRI) has been applied to investigate kidney oxygenation in 
human patients. These investigations reflect the progress of radiology 
from a primarily anatomic discipline to one that provides insight into 
tissue physiology. In particular, magnetic resonance imaging (MRI) is 
non-invasive, uses no ionizing radiation, and provides insight into disease 
development and tissue physiology.
Kidney International (2006) 70, 10–11. doi:10.1038/sj.ki.5001560
In this issue, research groups from 
Northwestern University (Chicago, Illi-
nois, USA) and the University of Berne 
(Switzerland) report having applied 
blood oxygen level-dependent (BOLD) 
contrast magnetic resonance imaging 
(MRI) to investigate kidney oxygena-
tion in human patients.1,2 Th ese investi-
gations refl ect the progress of radiology 
from a primarily anatomic discipline 
to one that provides insight into tissue 
physiology. Progress in instrumentation, 
computing power, and data analysis has 
revolutionized the abilities of radiologi-
cal techniques to provide non-invasive 
insight into disease development and 
tissue physiology. In particular, MRI 
is non-invasive and uses no ionizing 
radiation. Modern clinical magnetic 
resonance scanners can provide exquisite 
anatomy, but more importantly, magnetic 
resonance can provide images sensitive 
to multiple parameters, for example, 
longitudinal relaxation (T1 (=1/R1)), 
transverse relaxation (T2 (=1/R2) and 
(T2* (=1/R2*)), and diffusion, with 
additional separation of water, fat, and 
metabolite images. Th ese facets make 
MRI a complex discipline, but they open 
enormous opportunities for investigat-
ing tissue pathophysiology. Th e applica-
tion of appropriate spin physics can give 
insight into tissue perfusion, intracellular 
water diff usion, blood fl ow, and oxygena-
tion, which is most pertinent here.
The variation of the water proton 
nuclear magnetic resonance T2 with 
blood oxygenation was first reported 
by Th ulborn et al. some 20 years ago.3 
Ogawa et al.4 pioneered the application 
to tissues, and the BOLD approach has 
now become a mainstay for interrogat-
ing neurological function with so-called 
functional MRI. Th e observations are 
predicated on the paramagnetic proper-
ties of deoxyhemoglobin, which induces 
susceptibility gradients in blood, causing 
loss of signal in T2*-weighted magnetic 
resonance images. Conversion to oxyhe-
moglobin leads to signal gain.
A number of investigators5,6 have shown 
relationships between R2 or R2* and par-
tial pressure of oxygen (pO2) in blood, and 
an example is presented in Figure 1. In 
the range 4–148 torr, both R2 and R2* are 
sensitive to pO2, whereas R1 is essentially 
invariant. Ultimately, complex quadratic 
relationships are oft en found over the range 
0–760 torr, due to the sigmoidal binding 
of oxygen with hemoglobin. Th e forma-
tion of deoxyhemoglobin directly alters 
T2, and this has been successfully applied 
to estimate pO2 in major blood vessels or 
the heart, brain, and abdomen. In other 
tissues, it can be a little more complicated, 
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